SKB BIO-B (06990) announced that the company's board of directors has reviewed and approved a full circulation plan (H-share full circulation) for certain shareholders' holdings of no more than 3.5721 million domestic shares and 4.6422 million unlisted foreign shares of the company. On the same day, the company has submitted a filing application regarding H-share full circulation to the China Securities Regulatory Commission.

As of the announcement date, the H-share full circulation still requires obtaining all relevant approvals (including the filing notice from the China Securities Regulatory Commission), as well as the conversion of these shares into the company's H shares and approval from the Listing Committee of The Stock Exchange of Hong Kong Limited for the listing and trading of H shares on the Main Board of the Hong Kong Stock Exchange (conversion and listing). The final implementation scale of the H-share full circulation will depend on the status of these relevant approvals.